Records 1 - 30
| Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.
Targeted oncology 2022 Jun .
Tan Elaine S, Fan Wenyi, Knepper Todd C, Schell Michael J, Sahin Ibrahim H, Fleming Jason B, Xie H
| Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
Experimental oncology 2021 09 43 (3): 252-256.
Vlachou M S, Mauri D, Zarkavelis G, Ntellas P, Tagkas C, Gkoura S, Pentheroudakis
| KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis.
Caspian journal of internal medicine 2020 11 (4): 355-369.
Yari Abolfazl, Afzali Asiyeh, Aalipour Mostafa, Nakheai Mehran, Zahedi Mohammad Jav
| Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
Cancer medicine 2019 Dec .
Bylsma Lauren C, Gillezeau Christina, Garawin Tamer A, Kelsh Michael A, Fryzek Jon P, Sangaré Laura, Lowe Kimberly
| The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
Cancer medicine 2019 Aug .
Bylsma Lauren C, Dean Rebecca, Lowe Kimberly, Sangaré Laura, Alexander Dominik D, Fryzek Jon
| Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
Medicine 2017 Sep 96 (35): e7882.
Kwak Min Seob, Cha Jae Myung, Yoon Jin Young, Jeon Jung Won, Shin Hyun Phil, Chang Hye Jung, Kim Hyung Kyung, Joo Kwang Ro, Lee Joung
| Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
The pharmacogenomics journal 2016 Nov .
Morgen E K, Lenz H-J, Jonker D J, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis C S, Dobrovic A, O'Callaghan C J, Liu
| Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis.
Meta gene 2016 Sep 9 110-9.
Zhou Mingyi, Yu Ping, Hou Kezuo, Fu Lingyu, Chen Ying, Qu Jinglei, Qu Xiujuan, Liu Yunpeng, Zhang Jingdo
| Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
World journal of gastroenterology 2016 Aug 22 (30): 6944-54.
Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Granetto Cristina, Fabozzi Teresa, Miraglio Emanuela, Merlano Marco
| Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis.
Molecular and clinical oncology 2016 Jun 4 (6): 1017-1024.
Lin L I, Chen Lu-Lu, Wang You, Meng Xiang-Yu, Liang Chen, Zhou Fu-Xia
| Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
European journal of cancer (Oxford, England : 1990) 2016 Jan 55 122-130.
Rowland Andrew, Dias Mafalda M, Wiese Michael D, Kichenadasse Ganessan, McKinnon Ross A, Karapetis Christos S, Sorich Michael
| Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.
The British journal of surgery 2015 Sep 102 (10): 1175-83.
Brudvik K W, Kopetz S E, Li L, Conrad C, Aloia T A, Vauthey J
| FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
Oncotarget 2015 Aug .
Ying Hou-Qun, Wang Feng, Chen Xiao-Lin, He Bang-Shun, Pan Yu-Qin, Jie Chen, Liu Xian, Cao Wei-Jun, Peng Hong-Xin, Lin Kang, Wang Shu-K
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
British journal of cancer 2015 Jun 112 (12): 1888-94.
Rowland A, Dias M M, Wiese M D, Kichenadasse G, McKinnon R A, Karapetis C S, Sorich M
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Jan 26 (1): 13-21.
Sorich M J, Wiese M D, Rowland A, Kichenadasse G, McKinnon R A, Karapetis C
| BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis.
Chinese medical sciences journal = Chung-kuo i hsüeh k'o hsüeh tsa chih / Chinese Academy of Medical Sciences 2014 Dec 29 (4): 197-203.
Wang Qi, Hu Wei-guo, Song Qi-bin, Wei J
| Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Cancer medicine 2014 Oct 3 (5): 1385-95.
Langevin Scott M, Christensen Brock
| The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64.
Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M
| Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Molecular biology reports 2014 Mar 41 (3): 1291-8.
Cui Dandan, Cao Dan, Yang Yu, Qiu Meng, Huang Ying, Yi Che
| Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.
Archives of medical science : AMS 2014 Feb 10 (1): 1-9.
Huang Lulu, Liu Zhenfang, Deng Donghong, Tan Aihua, Liao Ming, Mo Zengnan, Yang Xiao
| EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2014 Feb 26 (1): 59-71.
Shen Wei-Dong, Chen Hong-Lin, Liu Peng-F
| PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis.
PloS one 2014 9 (9): e107926.
Shan Lianfeng, Li Ming, Ma Jianzhong, Zhang Huid
| The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.
OncoTargets and therapy 2014 7 1487-96.
Ying Hou-Qun, Wang Feng, He Bang-Shun, Pan Yu-Qin, Gao Tian-Yi, Xu Ye-Qiong, Li Rui, Deng Qi-Wen, Sun Hui-Lin, Wang Shu-K
| Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Cancer science 2013 Oct 104 (10): 1330-8.
Wen Feng, Tang Ruilei, Sang Yaxiong, Li Meng, Hu Qiancheng, Du Zedong, Zhou Yi, Zhang Pengfei, He Xiaofeng, Li Q
| Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Journal of digestive diseases 2013 Aug 14 (8): 409-16.
Xu Qi, Xu An Tao, Zhu Ming Ming, Tong Jin Lu, Xu Xi Tao, Ran Zhi H
| PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
Journal of cancer research and clinical oncology 2013 May 139 (5): 891-900.
Wu Shuangjie, Gan Yu, Wang Xinhai, Liu Jun, Li Mengjun, Tang Yif
| Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
International journal of cancer. Journal international du cancer 2013 Mar .
Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL
| EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
PloS one 2013 8 (2): e56205.
Jiang Zheng, Li Chunxiang, Li Fuyuan, Wang Xish
| The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.
PloS one 2013 8 (6): e65995.
Yuan Zi-Xu, Wang Xiao-Yan, Qin Qi-Yuan, Chen De-Feng, Zhong Qing-Hua, Wang Lei, Wang Jian-Pi
| Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Cancer chemotherapy and pharmacology 2012 Oct .
Chen J, Ye Y, Sun H, Shi G